WSTAM
AVEO

Wilbanks Smith & Thomas Asset Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-60
Closed -$2K – 1507
2018
Q3 		$2K Buy
+60
New +$1.54K ﹤0.01% 1467

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's AVEO Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2018, closing a stake of 60 shares — an estimated $2K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in AVEO in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 99 funds tracked by Wall St. Rank hold AVEO as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 60 AVEO Pharmaceuticals, Inc. shares in Q4 2018, an estimated $2K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's AVEO Pharmaceuticals, Inc. position peaked at $2K in Q3 2018.
  • 99 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.